Real‐world evidence of outcomes of oligometastatic hormone‐sensitive prostate cancer patients treated with metastasis‐directed therapy

To investigate characteristics and outcomes of oligometastatic hormone‐sensitive prostate cancer (mHSPC) patients undergoing metastases‐directed therapy (MDT) with external beam radiation therapy (EBRT).

[1]  T. Steuber,et al.  Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume. , 2023, European urology focus.

[2]  B. Tombal,et al.  Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. D'Amico,et al.  NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023. , 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

[4]  T. Steuber,et al.  Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis. , 2022, European urology focus.

[5]  J. Carles,et al.  Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design , 2022, The Lancet.

[6]  M. Graefen,et al.  PSMA PET predicts metastasis-free survival in the setting of salvage radiotherapy after radical prostatectomy. , 2021, Urologic oncology.

[7]  F. Saad,et al.  Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis , 2021, Prostate Cancer and Prostatic Diseases.

[8]  F. Saad,et al.  Non‐cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy , 2021, The Prostate.

[9]  M. Scorsetti,et al.  Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance , 2021, Medical Oncology.

[10]  H. Heinzer,et al.  Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies , 2021, Frontiers in Oncology.

[11]  F. Saad,et al.  Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis. , 2021, European urology focus.

[12]  L. Budäus,et al.  Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Observational Study , 2021, The Journal of urology.

[13]  M. Graefen,et al.  Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer , 2021, Prostate international.

[14]  M. Zelefsky,et al.  Clinical Outcomes of Combined Prostate- and Metastasis-Directed Radiation Therapy for the Treatment of De Novo Oligometastatic Prostate Cancer , 2020, Advances in radiation oncology.

[15]  K. Pienta,et al.  Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancer , 2020, Medical Oncology.

[16]  Ash A. Alizadeh,et al.  Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer , 2020, JAMA oncology.

[17]  C. Fiorino,et al.  Prostate cancer with low burden skeletal disease at diagnosis: outcome of concomitant radiotherapy on primary tumor and metastases. , 2020, The British journal of radiology.

[18]  P. Boutros,et al.  What Is Oligometastatic Prostate Cancer? , 2019, European urology focus.

[19]  R. Weichselbaum,et al.  Oligometastatic prostate cancer: Reality or figment of imagination? , 2018, Cancer.

[20]  N. Lawrentschuk,et al.  Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. , 2018, European urology.

[21]  M. Scorsetti,et al.  The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer , 2018, Cancer medicine.

[22]  E. Goetghebeur,et al.  Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  V. Laudone,et al.  A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer. , 2017, Urology.

[24]  R. Miralbell,et al.  Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences. , 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).

[25]  M. Roach,et al.  Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. , 2015, European urology.

[26]  C. Pipper,et al.  [''R"--project for statistical computing]. , 2008, Ugeskrift for laeger.

[27]  K. Pienta,et al.  Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations , 2017, Nature Reviews Urology.

[28]  F. Trippa,et al.  Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience , 2016, World Journal of Urology.